AstraZeneca, a pharmaceutical giant, has announced the launch of Evinova, a new health technology business that aims to share its expertise in clinical trial design and study delivery. This particular business will focus on providing solutions to trial sponsors, clinical research organizations, care teams and patients at scale. The company expects this initiative to reduce the time and cost of developing new drugs, bring care closer to patients’ homes and reduce the burden on healthcare systems.
In order to make Evinova’s solutions accessible to a wider audience, AstraZeneca has established extensive collaborations with Parekel and Fortre. These partnerships will make Evin’s digital health solutions available to a broad customer base, supporting the company’s mission to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.
AstraZeneca CEO Pascal Soriot expressed confidence in Evinova’s ability to combine scientific expertise with AI-enabled digital technologies at scale, offering a real opportunity for positive change in the healthcare industry. He stated that “Evinova represents a significant step forward in our commitment to improving patient outcomes and reducing healthcare costs.”
For more information about Evinova and its partnerships with Parekel and Fortre, contact Michael Susin at email@example.com.